202 related articles for article (PubMed ID: 28419476)
1. Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
Martini V; Gattazzo C; Frezzato F; Trimarco V; Pizzi M; Chiodin G; Severin F; Scomazzon E; Guzzardo V; Saraggi D; Raggi F; Martinello L; Facco M; Visentin A; Piazza F; Brunati AM; Semenzato G; Trentin L
Br J Haematol; 2017 Jul; 178(1):81-93. PubMed ID: 28419476
[TBL] [Abstract][Full Text] [Related]
2. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
Sivina M; Kreitman RJ; Arons E; Ravandi F; Burger JA
Br J Haematol; 2014 Jul; 166(2):177-88. PubMed ID: 24697238
[TBL] [Abstract][Full Text] [Related]
3. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
4. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase D-dependent CXCR4 down-regulation upon BCR triggering is linked to lymphadenopathy in chronic lymphocytic leukaemia.
Saint-Georges S; Quettier M; Bouyaba M; Le Coquil S; Laurienté V; Guittat L; Lévy V; Ajchenbaum-Cymbalista F; Varin-Blank N; Le Roy C; Ledoux D
Oncotarget; 2016 Jul; 7(27):41031-41046. PubMed ID: 27127886
[TBL] [Abstract][Full Text] [Related]
6. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
de Rooij MF; Kuil A; Geest CR; Eldering E; Chang BY; Buggy JJ; Pals ST; Spaargaren M
Blood; 2012 Mar; 119(11):2590-4. PubMed ID: 22279054
[TBL] [Abstract][Full Text] [Related]
7. Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
[TBL] [Abstract][Full Text] [Related]
8. Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia.
ten Hacken E; Scielzo C; Bertilaccio MT; Scarfò L; Apollonio B; Barbaglio F; Stamatopoulos K; Ponzoni M; Ghia P; Caligaris-Cappio F
Blood; 2013 Mar; 121(12):2264-73. PubMed ID: 23325840
[TBL] [Abstract][Full Text] [Related]
9. Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole.
Frezzato F; Trimarco V; Martini V; Gattazzo C; Ave E; Visentin A; Cabrelle A; Olivieri V; Zambello R; Facco M; Zonta F; Cristiani A; Brunati AM; Moro S; Semenzato G; Trentin L
Br J Haematol; 2014 Jun; 165(5):659-72. PubMed ID: 24606526
[TBL] [Abstract][Full Text] [Related]
10. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
Pavlasova G; Borsky M; Seda V; Cerna K; Osickova J; Doubek M; Mayer J; Calogero R; Trbusek M; Pospisilova S; Davids MS; Kipps TJ; Brown JR; Mraz M
Blood; 2016 Sep; 128(12):1609-13. PubMed ID: 27480113
[TBL] [Abstract][Full Text] [Related]
12. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
13. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Ponader S; Chen SS; Buggy JJ; Balakrishnan K; Gandhi V; Wierda WG; Keating MJ; O'Brien S; Chiorazzi N; Burger JA
Blood; 2012 Feb; 119(5):1182-9. PubMed ID: 22180443
[TBL] [Abstract][Full Text] [Related]
14. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
[TBL] [Abstract][Full Text] [Related]
15. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
[TBL] [Abstract][Full Text] [Related]
16. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
ten Hacken E; Burger JA
Pharmacol Ther; 2014 Dec; 144(3):338-48. PubMed ID: 25050922
[TBL] [Abstract][Full Text] [Related]
17. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
18. Arg kinase mediates CXCL12/CXCR4-induced invadopodia formation and invasion of glioma cells.
Chen L; Zhu M; Yu S; Hai L; Zhang L; Zhang C; Zhao P; Zhou H; Wang S; Yang X
Exp Cell Res; 2020 Apr; 389(1):111893. PubMed ID: 32035133
[TBL] [Abstract][Full Text] [Related]
19. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
20. Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.
Hasan MK; Rassenti L; Widhopf GF; Yu J; Kipps TJ
Leukemia; 2019 Mar; 33(3):653-661. PubMed ID: 30568170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
